Not a good buy right now for an impatient entry: price action is neutral-to-soft (MACD below zero) and there’s no proprietary buy signal today.
Options are pricing elevated uncertainty (very high IV into earnings), making the near-term risk/reward less attractive for an immediate stock purchase.
If you must take exposure immediately, MD is more of a “hold/monitor near support” setup than a momentum buy; a cleaner buy would be after a technical breakout above ~21.88 or a successful hold/rebound off ~20.44.
Intellectia signals: AI Stock Picker = no signal today; SwingMax = no recent signal.
Technical Analysis
Trend/Momentum: MACD histogram at -0.0576 (below 0) and negatively contracting → bearish momentum is fading, but trend is not bullish yet.
RSI: RSI(6) at 47.8 → neutral, no oversold bounce signal.
Moving averages: converging MAs → consolidation/range behavior rather than a directional trend.
Key levels: Pivot 21.157 (current 21.05 slightly below pivot = mild weakness). Resistance: 21.879 then 22.325. Support: 20.435 then 19.989.
Pattern-based probability (provided): modest upside bias over 1w/1m (+1.25% / +3.67%) but not strong enough to override the lack of momentum today.
Options Data
Bullish
Open Interest Put-Call Ratio
Bearish
Option Volume Put-Call Ratio
Positioning (OI): Put/Call OI = 0.19 → call open interest dominates (bullish-leaning positioning).
Flow (Volume): Put/Call volume = 1.45 with small absolute volume (puts 16 vs calls 11) → today’s trading flow is more defensive despite call-heavy OI.
Volatility: 30D IV 76.83 vs historical vol 29.13; IV percentile 88.45 → options are very expensive and imply a big move risk, consistent with upcoming earnings.
Activity: Today’s volume ~207.7% of 30D average → unusually active options day (heightened sentiment/positioning ahead of an event).
Technical Summary
Sell
7
Buy
2
Positive Catalysts
could re-rate the stock if results/guide are strong.
after a Q3 beat/guidance raise (supportive of upside if execution continues).
Neutral/Negative Catalysts
No bullish momentum signal today: MACD remains below zero and price is slightly under pivot resistance zone.
Event risk/expensive options: very high implied volatility into earnings increases the chance of a sharp move against a new immediate entry.
Fundamental top-line pressure: last reported quarter showed revenue decline YoY (weak demand/volume signal).
No news tailwinds in the last week and no notable hedge/insider accumulation trend reported recently.
Financial Performance
Latest quarter provided: 2025/Q3.
Revenue: $492.875M, down -3.58% YoY → top-line contraction.
Profitability: Net income $71.708M, up +268.85% YoY; EPS $0.84, up +265.22% YoY → strong bottom-line improvement (likely driven by margins/one-time items/cost actions; revenue trend still the key watch).
Overall: earnings power improved sharply, but the quality of growth is mixed due to declining revenue.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent change: (2025-11-10) Truist raised PT to $24 from $17; maintained Hold rating.
Street “pros” view: improved execution versus prior expectations (Q3 beat and guidance raise), implying upside toward mid-20s if momentum continues.
Street “cons” view: Hold rating signals valuation/visibility still not compelling enough for a full upgrade; revenue decline keeps the fundamental debate open.
Net takeaway: analysts acknowledge improvement but are not uniformly confident—supports a cautious stance rather than an immediate buy.
Wall Street analysts forecast MD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MD is 23.5 USD with a low forecast of 23 USD and a high forecast of 24 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast MD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MD is 23.5 USD with a low forecast of 23 USD and a high forecast of 24 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 20.830
Low
23
Averages
23.5
High
24
Current: 20.830
Low
23
Averages
23.5
High
24
Truist
David MacDonald
Hold
maintain
$17 -> $24
AI Analysis
2025-11-10
Reason
Truist
David MacDonald
Price Target
$17 -> $24
AI Analysis
2025-11-10
maintain
Hold
Reason
Truist analyst David MacDonald raised the firm's price target on Pediatrix Medical to $24 from $17 and keeps a Hold rating on the shares. The firm is updating its model to reflect the company's Q3 earnings beat and guidance raise, the analyst tells investors in a research note.
UBS
Neutral
maintain
$23
2025-11-05
Reason
UBS
Price Target
$23
2025-11-05
maintain
Neutral
Reason
UBS raised the firm's price target on Pediatrix Medical to $23 from $16.50 and keeps a Neutral rating on the shares. Pricing growth drove a strong Q3, and UBS expects stable hospital administrative fees in 2026, the analyst tells investors in a research note.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for MD
